PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
PolyPid Ltd. (Nasdaq: PYPD) announced it will release its third quarter 2022 financial results and operational updates on November 9, 2022, prior to the U.S. market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) announced it will release its third quarter 2022 financial results and operational updates on November 9, 2022, prior to the U.S. market opening. The company will host a conference call at 8:30 AM ET to discuss these results. PolyPid focuses on enhancing surgical outcomes through its PLEX technology, deploying drug delivery systems that provide controlled release of pharmaceuticals. Its lead candidate, D-PLEX100, is in Phase 3 trials for infection prevention following surgeries.
Positive
- Scheduled conference call indicates ongoing transparency with investors.
- D-PLEX100 in Phase 3 trials for preventing surgical site infections.
Negative
- None.
Details
News Market Reaction – PYPD
The recorded move for PYPD in the trading session of this news was -2.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, November 9, 2022 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register.vevent.com/register/BI5e06285152a24249a0330f025cefc01e |
| Webcast: | https://edge.media-server.com/mmc/p/c6nr79zi |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.